PD: BDP9066 (BDP-9066) is a novel, potent and selective MRCK (myotonic dystrophy-related Cdc42-binding kinase) inhibitor with anticancer activities. It exhibits IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. It acts by reducing substrate phosphorylation. BDP9066 leads to morphological changes in cancer cells along with inhibition of their motility and invasive character. It has therapeutic effect on skin cancer by reducing substrate phosphorylation.
Physicochemical Properties
| Molecular Formula | C20H24N6 |
| Molecular Weight | 348.444763183594 |
| Exact Mass | 348.21 |
| Elemental Analysis | C, 68.94; H, 6.94; N, 24.12 |
| CAS # | 2226507-04-4 |
| Related CAS # | (R)-BDP9066;2284549-25-1 |
| PubChem CID | 132275018 |
| Appearance | White to light brown solid powder |
| LogP | 2.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 26 |
| Complexity | 487 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | N1CCCC[C@@]21CN(C1C=CN=C3C=1C(C1C=CN=CN=1)=CN3)CCC2 |
| InChi Key | UELSMLDRSQFVHG-FQEVSTJZSA-N |
| InChi Code | InChI=1S/C20H24N6/c1-2-8-25-20(6-1)7-3-11-26(13-20)17-5-10-22-19-18(17)15(12-23-19)16-4-9-21-14-24-16/h4-5,9-10,12,14,25H,1-3,6-8,11,13H2,(H,22,23)/t20-/m0/s1 |
| Chemical Name | (6S)-8-(3-pyrimidin-4-yl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1,8-diazaspiro[5.5]undecane |
| Synonyms | BDP9066; BDP-9066; BDP 9066 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | BDP9066 has antiproliferative properties, with blood cancer cells exhibiting the highest level of activity. BDP9066 prevents SCC12 squamous cell carcinoma motility and invasion by inhibiting MLC phosphorylation [1]. |
| ln Vivo | Topical treatment of BDP9066 significantly lowers phosphorylated MRCKα S1003 staining and tumor volume [1]. |
| References |
[1]. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~10 mg/mL (~28.70 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8699 mL | 14.3497 mL | 28.6993 mL | |
| 5 mM | 0.5740 mL | 2.8699 mL | 5.7399 mL | |
| 10 mM | 0.2870 mL | 1.4350 mL | 2.8699 mL |